We investigated microtubule-associated protein 2 (MAP-2) immunoreactivity of hippocampal neurons and the potential role of royal jelly (RJ) in regulating MAP-2 during experimental hypothyroidism (HT). Thirty adult female Wistar albino rats were randomized into five groups: the control group was untreated, the sham control group was treated with 10 mg/kg 0.9% sterile saline injected intraperitoneally (i.p.), The RJ group was treated with 100 mg/kg RJ by oral gavage, the HT group was treated with 10 mg/kg propylthiouracil (PTU) i.p. to induce experimental hypothyroidism, and the HT + RJ group was treated with 10 mg/kg PTU i.p. + 100 mg/kg RJ by oral gavage. Oral and i.p. administrations were performed once daily for 20 days. Thyroid stimulating hormone (TSH) and free thyroxine (fT4) levels in the serum were measured biochemically, MAP-2 was measured immunohistochemically in the hippocampus and an immunohistochemical H score was calculated. MAP-2 immunoreactivity appeared in the cytoplasm of neuron cell bodies and dendrites in the hippocampal CA3 and CA1 regions in the control, sham control and RJ groups. MAP-2 immunoreactivity decreased significiantly in the HT group compared to control, sham control and RJ groups. Also, vascular dilation and swollen cells were observed following PTU administration. The degeneration that was observed in the HT group decreased by RJ administration. By contrast, MAP-2 immunoreactivity increased following administration of RJ. Experimental hypothyroidism reduced significiantly MAP-2 immunoreactivity in both the CA3 and CA1 regions and caused degeneration, including edema and vascular dilation, in the hippocampus. RJ increased MAP-2 expression and exhibited a therapeutic effect on the degenerative changes.

中文翻译：

---

蜂王浆增加甲状腺功能减退大鼠海马神经元中map-2的表达：一项免疫组织化学研究。

我们调查了海马神经元的微管相关蛋白2（MAP-2）免疫反应性和蜂王浆（RJ）在甲状腺功能减退症（HT）期间调节MAP-2的潜在作用。将30只成年雌性Wistar白化病大鼠随机分为五组：对照组不接受治疗，假对照组给予10 mg / kg腹腔内注射的0.9％无菌生理盐水（ip），RJ组给予100 mg / kg RJ进行治疗通过口服灌胃，HT组接受10 mg / kg丙硫氧嘧啶（PTU）腹膜内注射以诱发实验性甲状腺功能减退，HT + RJ组通过口服灌胃10 mg / kg PTU ip + 100 mg / kg RJ进行治疗。每天一次口服和腹膜内给药，持续20天。用生化法测定血清中的促甲状腺激素（TSH）和游离甲状腺素（fT4）水平，在海马中免疫组化测量MAP-2，并计算免疫组化H值。MAP-2免疫反应性出现在对照组，假对照组和RJ组的海马CA3和CA1区神经元细胞体的细胞质和树突中。与对照组，假对照组和RJ组相比，HT组的MAP-2免疫反应性显着降低。而且，在施用PTU后观察到血管扩张和细胞肿胀。RJ给药减少了HT组的变性。相反，施用RJ后MAP-2免疫反应性增加。实验性甲状腺功能减退症显着降低CA3和CA1区的MAP-2免疫反应性，并引起海马变性，包括水肿和血管扩张。